The industry must overcome enormous challenges in order to take the next steps in induced pluripotent stem cell technology.

Drug development needs to move more rapidly, but not at the expense of safety.

One analytical technique that is seeing increasing popularity, in part due to its precision and reproducibility, is capillary electrophoresis.

The drug development system is broken; the COVID-19 pandemic is an opportunity to take a bold step towards accessible and affordable therapies.

We’re making progress on standardizing single-use systems – and it could mean a more cost-effective supply chain.

Gene therapy manufacturers will need to focus on upstream filtration to minimize the risk of viral infection.

Lives and livelihoods depend on accelerating large molecule drug production, so biopharma companies must minimize defects and contamination.

Harnessing the potential of microphysiological systems to advance drug discovery.

How is the business of making medicine changing in light of the COVID-19 pandemic?